Jim Cramer says it's more than just the cloud. There are some astounding moves in the broader tech sector, too.
AstraZeneca shares edged higher Tuesday as investors shrugged off a mixed set of phase-3 results for the Anglo Swedish drug maker's Bydureon Exscel type II diabetes treatment.
Jim Cramer focuses on Blackberry, Exact Sciences, Splunk, Freeport-McMoRan and more.
Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.